Log in
Enquire now
‌

US Patent 10058599 Suppressor cell function inhibition following

Patent 10058599 was granted and assigned to Advaxis on August, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Advaxis
Advaxis
0
Current Assignee
Advaxis
Advaxis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
100585990
Patent Inventor Names
Reshma Singh0
Anu Wallecha0
Date of Patent
August 28, 2018
0
Patent Application Number
143839700
Date Filed
March 12, 2013
0
Patent Citations Received
‌
US Patent 11446369 Compositions and methods comprising KLK3 or FOLH1 antigen
‌
US Patent 10900044 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
0
‌
US Patent 11702664 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
0
Patent Primary Examiner
‌
Brian Gangle
0
Patent abstract

This invention provides methods and compositions for using a live attenuated Listeria for inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10058599 Suppressor cell function inhibition following

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.